Navigation Links
ViroPharma to Participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
Date:2/11/2011

EXTON, Pa., Feb. 11, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference at 2:40 P.M. ET on Thursday, February 17, 2011.  The conference is being held at the Roosevelt Hotel in New York City.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ViroPharma to Participate in the 29th Annual J.P. Morgan Healthcare Conference
2. ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program
3. ViroPharma to Release 2010 Second Quarter Financial Results on July 28, 2010
4. ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human])
5. ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final Open-Label Data
6. ViroPharma to Participate in Two May Healthcare Investor Conferences
7. ViroPharma to Present at Three November Healthcare Conferences
8. ViroPharma to Present at Four Additional Healthcare Conferences
9. ViroPharma to Present at Several Upcoming Healthcare Conferences
10. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... to a new market research report "In situ Hybridization Market by Technique (FISH, ... Laboratories, Academic and Research Institutions) - Global Forecast to 2021" published by MarketsandMarkets, ... 557.1 Million in 2016, growing at a CAGR of 5.8%. ... ... Logo ...
(Date:1/18/2017)... , Jan. 18, 2017   Parent Project ... fight to end Duchenne muscular dystrophy (Duchenne) , ... the New Jersey Institute of Technology (NJIT) and Talem ... exploration of robotic technology to assist people living ... incorporate NJIT,s technology – an embedded computer, software, a ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... more E&L expertise. Within Albany Molecular Research, Inc. (AMRI), the scientific staff dedicated ... year and is planned for further growth in 2017. Extractable & Leachable evaluations ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... Researchers from a new study ... not fall low enough after prostate cancer treatment, this indicates there is still remaining prostate ... of mortality. , “ The PSA test has always been an indicator of whether a ...
Breaking Biology Technology:
(Date:12/20/2016)... , Dec. 20, 2016 The ... sharing, rental and leasing is stoking significant interest ... radio frequency technology, Bluetooth low energy (BLE), biometrics ... as the next wave of wireless technologies in ... access system to advanced access systems opens the ...
(Date:12/16/2016)... Dec 16, 2016 Research and Markets has ... - Global Forecast to 2021" report to their offering. ... The biometric vehicle ... at a CAGR of 14.06% from 2016 to 2021. The market ... projected to reach 854.8 Million by 2021. The growth of the ...
(Date:12/15/2016)... ... announced the addition of the "Global Military Biometrics Market 2016-2020" ... military biometrics market to grow at a CAGR of 7.5% during the ... an in-depth market analysis with inputs from industry experts. The report covers ... report also includes a discussion of the key vendors operating in this ...
Breaking Biology News(10 mins):